Regulatory affairs (RA) is the backbone of drug development. It ensures that medicines reaching patients are safe, effective and of high quality. Regulatory professionals act as a bridge between pharmaceutical companies and health authorities, guiding drugs from the lab to the market.
Drug approval is a step-by-step journey
Whether in India or globally, drug approval follows a structured pathway:
Discovery → Preclinical studies → Clinical trials → Regulatory review → Market approval → Post-marketing surveillance
Step 1: Drug Discovery & Preclinical Studies
Before testing in humans, a drug is evaluated in laboratories and animals to study:
- Toxicity
- Pharmacokinetics (ADME)
- Initial safety profile
Only drugs showing acceptable safety move forward.
Step 2: Clinical Trials (Human Studies)
Clinical trials are conducted in phases:
- Phase I: Safety and dosage (small group of healthy volunteers)
- Phase II: Efficacy and side effects (patients with the disease)
- Phase III: Large-scale confirmation of safety and effectiveness
- Phase IV: Post-marketing safety monitoring (after approval)
Drug Approval in India,
In India, drug approvals are governed by Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act and NDCT Rules, 2019.
Key steps include,
- Submission of clinical trial application
- Ethics Committee approval
- Review by Subject Expert Committees (SEC)
- Permission from Drug Controller General of India (DCGI)
- Marketing authorization
Drug approval globally,
United States
- In the US, approvals are handled by Food and Drug Administration (FDA).
- Companies submit an Investigational New Drug (IND) application
- After trials, a New Drug Application (NDA) or Biologics License Application (BLA) is reviewed
Europe
- In Europe, approvals are overseen by the European Medicines Agency (EMA).
- Uses a centralized procedure for EU-wide approval
- Scientific evaluation by expert committees
Global Harmonization:
- To streamline approvals worldwide, guidelines are harmonized through the International Council for Harmonisation (ICH). These cover:
Quality (ICH Q)
Safety (ICH S)
Efficacy (ICH E)
Multidisciplinary topics (ICH M)
Step 3: Marketing Authorization
Once data proves that benefits outweigh risks, regulators grant approval to market the drug with:
- Approved indications
- Labeling and prescribing information
- Risk management plans
Step 4: Post-Marketing Surveillance
Approval is not the end. Regulators continuously monitor drugs through:
- Adverse drug reaction (ADR) reporting
- Pharmacovigilance programs
- Safety updates and label changes
Why RA?
- Protects patient safety
- Prevents unsafe or ineffective drugs from entering the market
- Ensures ethical clinical research
- Builds public trust in medicines
Regulatory affairs ensures that every pill, injection or vaccine that we use has passed through rigorous scientific and ethical checks, both in India and globally.
MBH/AB